Founded in 1973, Abingworth is a specialized investment firm focused exclusively on the life sciences sector. The company provides financing to private and public companies at all stages of development, from start-ups to established enterprises. Their investment strategies include venture, growth, and clinical co-development. In 2022, Abingworth was acquired by Carlyle (NASDAQ: CG) and now operates as part of Carlyle's Global Private Equity platform, continuing its mission to fund and build biotech companies that advance therapeutic products.

Founded in

United Kingdom